期刊
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
卷 20, 期 1, 页码 3-10出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1078155212472702
关键词
Malignant melanoma; immunotherapy; anti-CTLA-4 antibodies; anti-PD-1 antibodies; ipilimumab
Individuals with malignant melanoma present a variety of immune abnormalities including but not limited to cellular immune dysfunction, antigen presentation deficits, and cytokine production defects. Therefore, enhancing the immune system potential represents an appealing avenue for melanoma therapy. The authors review the immune therapies currently in clinical use as well as the most promising immunotherapy candidates. Ipilimumab, a monoclonal antibody against the CTLA-4, was approved for the therapy of advanced melanoma in 2011. In addition, sizeable anti-melanoma activity has recently been shown with the use of other agents including anti-PD-1/anti-PD-1 ligand antibodies. Consequently, these experimental immunotherapy agents may soon become important items in the anti-melanoma armamentarium.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据